|
|
|
|
Relevance of Osteoproliferation as an Outcome Parameter in Ankylosing Spondylitis
_ Relevance of Osteoproliferation as an Outcome Parameter in Ankylosing Spondylitis.
|
|
|
Adalimumab Decreases Rate of Anterior Uveitis in Ankylosing Spondylitis: Presented at AAO
-- The anti-tumour necrosis factor inhibitor adalimumab appears to effectively inhibit the development of anterior-uveitis episodes in patients with ankylosing spondylitis, according to new research presented here at the American Academy of...
|
|
|
Ankylosing Spondylitis
_ Ankylosing Spondylitis.
|
|
|
Infliximab Improves Symptoms of Ankylosing Spondylitis, but Damage Continues
By David Douglas NEW YORK (Reuters Health) Oct 31 - In patients with ankylosing spondylitis, infliximab does not inhibit structural damage, although it may have other beneficial effects, according to European and US researchers.'Although...
|
|
|
Infliximab improves symptoms of ankylosing spondylitis, but damage continues
In patients with ankylosing spondylitis, infliximab does not inhibit structural damage, although it may have other beneficial effects, according to European and US researchers.'Although disappointing,' lead investigator Dr. Dsire van...
|
|
|
Adalimumab Does Not Inhibit Radiographic Progression in Ankylosing Spondylitis After 2 Years of Treatment: Pre
-- Adalimumab therapy has not resulted in inhibition of radiographic progression in patients with ankylosing spondylitis (AS) who were treated for 2 years despite providing substantial and significant improvements in clinical efficacy,...
|
|
|
New study shows ENBREL(R) (etanercept) is more effective than a DMARD in the treatment of symptoms of Ankylosi
MAIDENHEAD, England - Data from another study supported the use of ENBREL for up to five years in Ankylosing Spondylitis patients New safety and efficacy data for active ankylosing spondylitis (AS) patients treated with ENBREL(R)...
|
